Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial

被引：0
|
作者：
Matteo Dalla Chiesa
Gianluca Tomasello
Sebastiano Buti
Rodrigo Kraft Rovere
Matteo Brighenti
Silvia Lazzarelli
Gianvito Donati
Rodolfo Passalacqua
机构：
[1] Azienda Ospedaliera di Cremona,Departments of Medical Oncology and Biostatistics
[2] Azienda Istituti Ospitalieri,Medical Oncology Division
来源：
Cancer Chemotherapy and Pharmacology | 2011年 / 67卷
关键词：
Sequential chemotherapy; Irinotecan; Oxaliplatin; Docetaxel; Cisplatin; 5-Fluorouracil; Gastric cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：41 / 48
页数：7
相关论文
共 50 条
  • [31] 5-FLUOROURACIL, FOLINIC ACID, ETOPOSIDE AND CISPLATIN CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC CARCINOMA OF THE ESOPHAGUS
    STAHL, M
    WILKE, H
    MEYER, HJ
    PREUSSER, P
    BERNS, T
    FINK, U
    ACHTERRATH, W
    KNIPP, H
    HARSTRICK, A
    BERGER, M
    SCHMOLL, HJ
    EUROPEAN JOURNAL OF CANCER, 1994, 30A (03) : 325 - 328
  • [32] Cardiotoxicity in 5-fluorouracil folinic acid treatment for metastatic colorectal cancer
    Käfer, G
    Achtnich, M
    Willer, A
    Weiss, A
    Queisser, W
    ONKOLOGIE, 1998, 21 (04): : 324 - 327
  • [33] Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial
    D Santini
    F Graziano
    V Catalano
    M Di Seri
    E Testa
    AM Baldelli
    P Giordani
    A La Cesa
    B Spalletta
    B Vincenzi
    A Russo
    M Caraglia
    V Virzi
    S Cascinu
    G Tonini
    BMC Cancer, 6
  • [34] CARDIOTOXICITY OF 5-FLUOROURACIL IN COMBINATION WITH FOLINIC ACID IN PATIENTS WITH GASTROINTESTINAL CANCER
    SCHOBER, C
    PAPAGEORGIOU, E
    HARSTRICK, A
    BOKEMEYER, C
    MUGGE, A
    STAHL, M
    WILKE, H
    POLIWODA, H
    HIDDEMANN, W
    KOHNEWOMPNER, CH
    WEISS, J
    PREISS, J
    SCHMOLL, HJ
    CANCER, 1993, 72 (07) : 2242 - 2247
  • [35] PHASE-I TRIAL OF DIPYRIDAMOLE WITH 5-FLUOROURACIL AND FOLINIC ACID
    BUDD, GT
    JAYARAJ, A
    GRABOWSKI, D
    ADELSTEIN, D
    BAUER, L
    BOYETT, J
    BUKOWSKI, R
    MURTHY, S
    WEICK, J
    CANCER RESEARCH, 1990, 50 (22) : 7206 - 7211
  • [36] PHASE-I TRIAL OF INTRAPERITONEAL 5-FLUOROURACIL AND FOLINIC ACID
    BUDD, GT
    SCHREIBER, MJ
    STEIGER, E
    BUKOWSKI, RM
    WEICK, JK
    CLINICAL RESEARCH, 1984, 32 (04): : A765 - A765
  • [37] Biweekly oxaliplatin plus irinotecan and folinic acid-modulated 5-fluorouracil: a phase II study in pretreated patients with metastatic colorectal cancer
    Comella, Pasquale
    Massidda, Bruno
    Palmeri, Sergio
    Putzu, Carlo
    De Rosa, Vincenzo
    Izzo, Francesco
    Fiore, Francesco
    Casaretti, Rossana
    Sandomenico, Claudia
    ANTI-CANCER DRUGS, 2006, 17 (08) : 985 - 992
  • [38] Paclitaxel, 5-fluorouracil, and folinic acid in metastatic breast cancer: BRE-26, a phase II trial
    Johnson, DH
    Paul, D
    Hande, KR
    SEMINARS IN ONCOLOGY, 1997, 24 (01) : S22 - S25
  • [39] Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil - A prospective cohort study
    Moehler, M
    Gutzler, F
    Steinmann, S
    Boehme, M
    Raeth, U
    Stremmel, W
    Galle, PR
    Rudi, J
    CHEMOTHERAPY, 2003, 49 (1-2) : 85 - 89
  • [40] FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC):: a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG)
    Souglakos, J
    Androulakis, N
    Syrigos, K
    Polyzos, A
    Ziras, N
    Athanasiadis, A
    Kakolyris, S
    Tsousis, S
    Kouroussis, C
    Vamvakas, L
    Kalykaki, A
    Samonis, G
    Mavroudis, D
    Georgoulias, V
    BRITISH JOURNAL OF CANCER, 2006, 94 (06) : 798 - 805
12345